ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 24 of 68
Up
JMBS 2021, 6(5): 169–177
https://doi.org/10.26693/jmbs06.05.169
Clinical Medicine

Radiofrequency Ablation Impact on the Morpho-Functional State of the Heart in Patients with Atrial Fibrillation and Chronic Heart Failure

Zolotarova T. V.
Abstract

The purpose of the study was to evaluate the radiofrequency ablation impact on the morpho-functional state of the heart in patients with atrial fibrillation and chronic heart failure with preserved ejection fraction based on 2-year follow-up. Materials and methods. The study included 194 patients with an average age of 59.3±8.5 years with atrial fibrillation and concomitant heart failure with preserved left ventricular ejection fraction of I-III functional class of New York Heart Association. Patients were divided into 2 groups: 136 patients who underwent radiofrequency catheter ablation and 58 patients in the control group who did not undergo intervention and continued antiarrhythmic pharmacotherapy. Patients were comparable in terms of basic clinical and demographic indicators. In order to assess the morpho-functional state of the heart, transthoracic echocardiography was performed at the stage of inclusion in the study and 2 years after. Results and discussion. According to the results of the analysis in the radiofrequency catheter ablation group 2 years after the intervention revealed: a statistically significant decrease in the mean end-systolic diameter of the left ventricle (3.3±0.48 cm versus 3.2±0.41cm, p <0.001); decreased size of the left atrium (4.3±0.71 cm versus 4.2±0.30 cm, p <0.001); left ventricular ejection fraction increased significantly (61.9±7.14% versus 63.9±5.65%, p <0.001); the E/e' ratio decreased statistically significantly (11.9±1.65 versus 9.4±1.48; p <0.001) and the left ventricular myocardial mass index (118.3±25.04 g/m2 versus 116.4±18.04 g/m2; p=0.045). In the pharmacotherapy group there were: a statistically significant increase in the average end-systolic size of the left ventricle (3.61±0.45 cm versus 3.63±0.41, p=0.007); statistically significant increased left atrium (4.3±0.61 cm versus 4.4±0.36; p <0.001) and the right atrium (4.1±0.52 cm versus 4.2±0.26; p <0.001); decreased left ventricular ejection fraction (58.1±6.12% versus 56.6±6.11; p <0.001); increased values of the ratio E/e' (12.1±1.63 versus 12.7±1.27; p=0.002) and decreased level of the left ventricular myocardial mass index (120.5±24.05 g/m2 versus 118.3±20.13 g/m2; p=0.044). Conclusion. Radiofrequency ablation of atrial fibrillation in patients with heart failure with preserved left ventricular ejection fraction to control sinus rhythm is associated with improved morpho-functional state of the heart at the 2-year follow-up compared with antiarrhythmic pharmacotherapy strategy: the left ventricular ejection fraction increases, the left ventricular diastolic function improves according to the E/e' value, the size of the left atrium decreases

Keywords: morpho-functional state, heart failure, ablation, atrial fibrillation

Full text: PDF (Ukr) 400K

References
  1. Borlaug B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiolog. 2020; 17(9): 559-573. https://www.ncbi.nlm.nih.gov/pubmed/32231333. https://doi.org/10.1038/s41569-020-0363-2
  2. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016; 18(3): 242-252. https://www.ncbi.nlm.nih.gov/pubmed/26727047. https://doi.org/10.1002/ejhf.483
  3. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297-3317. https://www.ncbi.nlm.nih.gov/pubmed/31504452. https://doi.org/10.1093/eurheartj/ehz641
  4. Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Col Cardiol. 2016; 68(2): 2217-2228. https://www.ncbi.nlm.nih.gov/pubmed/27855811. https://doi.org/10.1016/j.jacc.2016.08.048
  5. Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation. 2020; 141(1): 4-6. https://www.ncbi.nlm.nih.gov/pubmed/31887078. https://doi.org/10.1161/circulationaha.119.042996
  6. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42(36): 3599-3726. https://www.ncbi.nlm.nih.gov/pubmed/34447992. https://doi.org/10.1093/eurheartj/ehab368
  7. Rattka M, Pott A, Kühberger A, Weinmann K, Scharnbeck D, Stephan T, et al. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. Europace. 2020; 22(9): 1328-1336. https://www.ncbi.nlm.nih.gov/pubmed/32449907. https://www.ncbi.nlm.nih.gov/pmc/articles/7478318. https://doi.org/10.1093/europace/euaa101
  8. Black-Maier E, Ren X, Steinberg BA, Green CL, Barnett AS, Rosa NS, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2018; 15(5): 651-657. https://www.ncbi.nlm.nih.gov/pubmed/29222043. https://doi.org/10.1016/j.hrthm.2017.12.001
  9. Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, et al. Efficacy, Safety, and Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction. J Am Col Cardiol. 2013; 62(20): 1857-1865. https://www.ncbi.nlm.nih.gov/pubmed/23916940. https://doi.org/10.1016/j.jacc.2013.07.020
  10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-2200. https://www.ncbi.nlm.nih.gov/pubmed/27206819. https://doi.org/10.1093/eurheartj/ehw128
  11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893-2962. https://www.ncbi.nlm.nih.gov/pubmed/27567408. https://doi.org/10.1093/eurheartj/ehw210
  12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J. 2015; 16(3): 233-271. https://www.ncbi.nlm.nih.gov/pubmed/25712077. https://doi.org/10.1093/ehjci/jev014
  13. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. Circulation. 2021; 143: 1377-1390. https://www.ncbi.nlm.nih.gov/pubmed/33554614. https://doi.org/10.1161/CIRCULATIONAHA.120.050991
  14. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018; 378(5): 417-427. https://www.ncbi.nlm.nih.gov/pubmed/29385358. https://doi.org/10.1056/nejmoa1707855
  15. Ichijo S, Miyazaki S, Kusa S, Nakamura H, Hachiya H, Kajiyama T, et al. Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure. J Cardiol. 2018; 72(3): 240-246. https://www.ncbi.nlm.nih.gov/pubmed/29609877. https://doi.org/10.1016/j.jjcc.2018.02.012
  16. Zhu M, Zhou X, Cai H, Wang Z, Xu H, Chen S, et al. Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure. Medicine (Baltimore). 2016; 95(30): e4377. https://www.ncbi.nlm.nih.gov/pubmed/27472728. https://www.ncbi.nlm.nih.gov/pmc/articles/5265865. https://doi.org/10.1097/md.0000000000004377
  17. Ma Y, Bai F, Qin F, Li Y, Tu T, Sun C, et al. Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018; 18(1): 165. https://www.ncbi.nlm.nih.gov/pubmed/30103676. https://www.ncbi.nlm.nih.gov/pmc/articles/6090632. https://doi.org/10.1186/s12872-018-0904-3
  18. Kagawa Y, Fujii E, Fujita S, Ito M. Association between left atrial reverse remodeling and maintenance of sinus rhythm after catheter ablation of persistent atrial fibrillation. Heart Vessels. 2019; 35(2): 239-245. https://www.ncbi.nlm.nih.gov/pubmed/31346694. https://www.ncbi.nlm.nih.gov/pmc/articles/6981322. https://doi.org/10.1007/s00380-019-01475-1